Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
In the last 90 days, Protara Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Protara Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 33
- −2 vs. Q1 2022
- Shares held
- 5.93M
- −568.4K (−8.7%) vs. Q1 2022
- Total value
- $18.4M
- −$14.8M (−44.6%) vs. Q1 2022
- New holders
- 3
- 7 more added
- Sold out
- 5
- 14 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 100 | $0 | 0.00% | −46−31.5% | Reduced |
| American Portfolios Advisors | 100 | $293 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 566 | $1.00K | 0.00% | +6+1.1% | Added |
| Federated Hermes, Inc. | 380 | $1.00K | 0.00% | −46−10.8% | Reduced |
| JPMorgan Chase & Co | 352 | $1.00K | 0.00% | +352 | New |
| UBS Group AG | 1,271 | $4.00K | 0.00% | +697+121.4% | Added |
| Tower Research Capital LLC (TRC) | 1,807 | $5.00K | 0.00% | +1,807 | New |
| Morgan Stanley | 2,454 | $7.00K | 0.00% | −4,102−62.6% | Reduced |
| Acadian Asset Management LLC | 6,314 | $19.0K | 0.00% | −5,416−46.2% | Reduced |
| Virtu Financial LLC | 10,103 | $30.0K | 0.00% | +10,103 | New |
| Susquehanna International Group, LLP | 15,969 | $47.0K | 0.00% | +2,230+16.2% | Added |
| Bank of New York Mellon Corp | 17,907 | $53.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,019 | $59.0K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 25,666 | $75.0K | 0.00% | −1,925−7.0% | Reduced |
| Dimensional Fund Advisors LP | 28,700 | $84.0K | 0.00% | −1,906−6.2% | Reduced |
| State Street Corp | 30,900 | $91.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 38,508 | $113.0K | 0.00% | −408−1.0% | Reduced |
| Two Sigma Advisers, LP | 53,118 | $156.0K | 0.00% | −12,800−19.4% | Reduced |
| Two Sigma Investments, LP | 53,548 | $157.0K | 0.00% | −35,231−39.7% | Reduced |
| Renaissance Technologies LLC | 54,200 | $159.0K | 0.00% | +16,600+44.1% | Added |
| Assenagon Asset Management S.A. | 58,389 | $171.0K | 0.00% | +14,648+33.5% | Added |
| Millennium Management LLC | 60,784 | $178.0K | 0.00% | −11,566−16.0% | Reduced |
| Bridgeway Capital Management, LLC | 64,000 | $188.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 83,644 | $245.0K | 0.00% | +1,680+2.0% | Added |
| DLD Asset Management, LP | 157,349 | $461.0K | 0.04% | −72,182−31.4% | Reduced |
| Baker Bros. Advisors LP | 199,671 | $585.0K | 0.00% | 00.0% | Unchanged |
| Boxer Capital, LLC | 209,227 | $613.0K | 0.04% | 00.0% | Unchanged |
| Citadel Advisors LLC | 242,571 | $711.0K | 0.00% | −163,677−40.3% | Reduced |
| Ikarian Capital, LLC | 257,853 | $756.0K | 0.31% | −38,573−13.0% | Reduced |
| Perceptive Advisors LLC | 290,051 | $850.0K | 0.03% | −93,475−24.4% | Reduced |
| Vanguard Group Inc | 427,404 | $1.25M | 0.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 830,641 | $2.43M | 0.05% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,684,167 | $8.88M | 4.00% | +10,136+0.4% | Added |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −152,847−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −16,313−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −12,872−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −2,510−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −745−100.0% | Sold out |